There’s a different equity story being told by sentiment: Fortress Biotech Inc. (FBIO).

As of close of business last night, Fortress Biotech Inc.’s stock clocked out at $0.99, down -3.98% from its previous closing price of $1.03. In other words, the price has decreased by -$0.0410 from its previous closing price. On the day, 692566 shares were traded. FBIO stock price reached its highest trading level at $1.0715 during the session, while it also had its lowest trading level at $0.9702.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



To gain a deeper understanding of FBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 1.65 whereas as Long-Term Debt/Eq ratio is at 1.50.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on August 04, 2022, initiated with a Buy rating and assigned the stock a target price of $6.

On October 02, 2020, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $9.

On December 18, 2019, B. Riley FBR started tracking the stock assigning a Buy rating and target price of $9.B. Riley FBR initiated its Buy rating on December 18, 2019, with a $9 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 when ROSENWALD LINDSAY A MD bought 100,000 shares for $0.68 per share. The transaction valued at 67,960 led to the insider holds 11,730,324 shares of the business.

ROSENWALD LINDSAY A MD bought 5,000 shares of FBIO for $2,800 on Nov 30. The PRESIDENT, CEO & CHAIRMAN now owns 11,630,324 shares after completing the transaction at $0.56 per share. On Nov 30, another insider, Jin David, who serves as the Chief Financial Officer of the company, bought 5,000 shares for $0.56 each. As a result, the insider paid 2,800 and bolstered with 1,402,829 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.48 while its Price-to-Book (P/B) ratio in mrq is 1.43.

Stock Price History:

Over the past 52 weeks, FBIO has reached a high of $2.31, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is 0.7322, while the 200-Day Moving Average is calculated to be 0.8971.

Shares Statistics:

It appears that FBIO traded 388.58K shares on average per day over the past three months and 660.54k shares per day over the past ten days. A total of 89.42M shares are outstanding, with a floating share count of 79.77M. Insiders hold about 22.80% of the company’s shares, while institutions hold 30.10% stake in the company. Shares short for FBIO as of Oct 13, 2022 were 591.35k with a Short Ratio of 0.80M, compared to 623.44k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.55% and a Short% of Float of 0.75%.

Earnings Estimates

As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.15 and a low estimate of -$0.57, while EPS last year was -$0.26. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.02 and low estimates of -$0.58.

Analysts are recommending an EPS of between -$0.59 and -$0.98 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is -$0.39, with 5 analysts recommending between $2.02 and -$2.14.

Revenue Estimates

In the current quarter, 6 analysts expect revenue to total $20.83M. It ranges from a high estimate of $22.93M to a low estimate of $17.49M. As of the current estimate, Fortress Biotech Inc.’s year-ago sales were $21.09M, an estimated decrease of -1.20% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $22.62M, an increase of 23.80% over than the figure of -$1.20% in the same quarter last year. There is a high estimate of $26.62M for the next quarter, whereas the lowest estimate is $15.43M.

A total of 6 analysts have provided revenue estimates for FBIO’s current fiscal year. The highest revenue estimate was $91.8M, while the lowest revenue estimate was $77.2M, resulting in an average revenue estimate of $86.73M. In the same quarter a year ago, actual revenue was $68.79M, up 26.10% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $148.53M in the next fiscal year. The high estimate is $244.84M and the low estimate is $100.85M. The average revenue growth estimate for next year is up 71.30% from the average revenue estimate for this year.